

April 7, 2016



# Trevena to Present at the Needham & Company 15th Annual Healthcare Conference

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company will be webcasting its corporate presentation at the Needham & Company 15th Annual Healthcare Conference on Wednesday, April 13, 2016 at 10:00 a.m. EDT in New York.

To access the live audio webcast of the presentation, please visit the "Investors" section of the company's website at [www.trevenainc.com](http://www.trevenainc.com). Following the conclusion of the presentation, the webcast will be archived for 30 days.

## About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified four biased ligand product candidates – oliceridine (TRV130) to treat moderate to severe acute pain intravenously (Phase 3), TRV027 to treat acute heart failure (Phase 2b), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for acute episodic migraine and other CNS disorders (preclinical).

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20160407005258/en/>

Trevena, Inc.  
Jonathan Violin, Ph.D.  
Sr. Director, Investor Relations  
610-354-8840 x231  
[jviolin@trevenainc.com](mailto:jviolin@trevenainc.com)

Source: Trevena, Inc.